Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

Annie Killoran, MD, MS

Portrait
Clinical Assistant Professor of Neurology

Education

MS, Pathology and Molecular Medicine, Queen’s University
MD, Medicine, University College Dublin, National University of Ireland
Resident, Neurology, Michigan State University
Fellow, Movement Disorders - Experimental Therapeutics, University of Rochester Medical Center

Publications

Schultz, J. L., Kamholz, J. A., Killoran, A., Tereshchenko, A., Bruss, A., Bernard, A., Koscik, T. A. & Nopoulos, P. C. (2018). The Autonomic Nervous System as a Potential Target for Disease Modification of Huntington Disease. Enroll-HD Congress.

Schultz, J. L., Kamholz, J. A., Moser, D. J., Killoran, A. & Nopoulos, P. C. (2018). Tetrabenazine Use is Associated with Cognitive Decline in Huntington Disease. Enroll-HD Congress.

Schultz, J. L., Nopoulos, P. C., Killoran, A. & Kahmolz, J. A. (2018). Delayed Disease Onset with Atorvastatin Use in Huntington Disease. Enroll-HD Congress.

Schultz, J. L., Killoran, A., Napoulos, P. C., Chabal, C. C., Moser, D. J. & Kamholz, J. A. (2018). Evaluating depression and suicidality in tetrabenazine users with Huntington disease.

Mendez, A. A., Bosco, A., Abdel-Wahed, L., Palmer, K., Jones, K. A. & Killoran, A. (2018). A Fatal Case of HSV Encephalitis with Two False-Negative PCRs. Case Reports in Neurology. Case Rep Neurol.

Schultz, J. L., Nopoulos, P. C., Killoran, A. & Kahmolz, J. A. (2018). Statin Use and Delayed Onset of Huntington Disease. Movement Disorders.

Schultz, J. L., Killoran, A., Napoulos, P. C., Chabal, C. C., Moser, D. J. & Kamholz, J. A. (2018). Evaluating Depression and Suicidality in Tetrabenazine Users with Huntington Disease. Enroll-HD Congress.

Schultz, J. L., Kamholz, J., Napoulos, P. c. & Killoran, A. (2018). Comparing risperidone and olanzapine to tetrabenazine for the management of chorea in Huntington Disease. Movement Disorders.

Schultz, J., Kamholz, J., Napoulos, P., Killoran, A. (2018). A. Comparing risperidone and olanzapine to tetrabenazine for the management of chorea in Huntington Disease. Neurotherapeutics.

Schultz, J., Kamholz, J., Moser, D., Killoran, A., McIlrath, A., Doom, J. & Nopoulos, P. (2018). Tetrabenazine and Acceleration of Huntington Disease. Neurotherapeutics.

Killoran, A. (2017). The Clinical Features of Huntington's Disease. In C. Hughes (Eds.) Huntington's Disease: Prevalence, Pathogenesis and Treatment. Nova Science Publishers.

Killoran, A., Biglan, K. (2016). Biomarkers for Huntington’s disease: a brief overview. Journal of Rare Disease Research & Treatment., 1(2), 46-50.

Killoran, A., Biglan, K. M. (2014). Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?. Movement disorders : official journal of the Movement Disorder Society, 29(11), 1404-13. PMID: 25164707.

Killoran, A., Biglan, K. M. (2014). Movement, Facial. In D. Weisbrot , A. Ettinger (Eds.) Neurological Differential Diagnosis: A Case-based Approach. pp. 247-249. Cambridge University Press. PMID: 1107014557.

Killoran, A., Biglan, K. M., Jankovic, J., Eberly, S., Kayson, E., Oakes, D., Young, A. B. & Shoulson, I. (2013). Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology, 80(22), 2022-7. PMID: 23624566.

Abdolahi, A., Scoglio, N., Killoran, A., Dorsey, E. R. & Biglan, K. M. (2013). Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. Parkinsonism & related disorders, 19(2), 218-21. PMID: 23102808.

Biglan, K. M., Zhang, Y., Long, J. D., Geschwind, M., Kang, G. A., Killoran, A., Lu, W., McCusker, E., Mills, J. A., Raymond, L. A., Testa, C., Wojcieszek, J. & Paulsen, J. S. (2013). Refining the diagnosis of Huntington disease: the PREDICT-HD study. Frontiers in aging neuroscience, 5, 12. PMID: 23565093.

Killoran, A., Biglan, K. M. (2012). 8-OHdG: its (limited) potential as a biomarker for Huntington's disease. (Vols. 6). (6), pp. 777-80. Biomarkers in medicine. PMID: 23227841.

Killoran, A. (2012). Ask the Experts. Neurology Now, 8(2), 35. DOI: 10.1097/01.nnn.0000414219.75201.0b.

Killoran, A., Biglan, K. M. (2012). Therapeutics in Huntington's Disease. Current treatment options in neurology. PMID: 22314929.

Killoran, A., Marshall, F. (In Press). Parkinsonian Syndromes: Co 1 tricobasal degeneration. In S. Gilman , J. Markovac (Eds.) Neurobiology of disease. (2nd ed.) Oxford University Press.

Thompson, M. D., Killoran, A., Percy, M. E., Nezarati, M., Cole, D. E. & Hwang, P. A. (2006). Hyperphosphatasia with neurologic deficit: a pyridoxine-responsive seizure disorder?. Pediatric neurology, 34(4), 303-7. PMID: 16638507.

Bouwman, C. W., Kohli, M., Killoran, A., Touchie, G. A., Kadner, R. J. & Martin, N. L. (2003). Characterization of SrgA, a Salmonella enterica serovar Typhimurium virulence plasmid-encoded paralogue of the disulfide oxidoreductase DsbA, essential for biogenesis of plasmid-encoded fimbriae. Journal of bacteriology, 185(3), 991-1000. PMID: 12533475.

Notley, C., Killoran, A., Cameron, C., Wynd, K., Hough, C. & Lillicrap, D. (2002). The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Human gene therapy, 13(13), 1583-93. PMID: 12228013.